Skip to main content

Rhythm Pharmaceuticals, Inc.

corporate_fare Company Profile

Rhythm Pharmaceuticals, Inc.

RYTM·NASDAQ·Life Sciences·CIK 0001649904

We are a global, commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. We develop melanocortin-4 receptor (MC4R) agonists, which are precision medicines for hyperphagia and severe obesity caused by rare MC4R pathway diseases. These diseases include acquired or congenital hypothalamic obesity, Bardet-Biedl syndrome (BBS), and Prader-Willi syndrome (PWS). The MC4R pathway in the brain regulates hunger, caloric intake, and energy expenditure, impacting body weight. Our lead product, IMCIVREE (setmelanotide), is an MC4R agonist for which we hold worldwide rights. It is marketed in the United States, European Union (EU), United Kingdom, Canada, and other countries and regions for certain rare MC4R pathway diseases, including BBS. We are also developing two earlier-stage investigational MC4R agonists with global rights: bivamelagon (formerly LB54640), an oral small molecule, and RM-718, designed for weekly subcutaneous administration. These are designed to be highly selective for MC4R and are not expected to cause hyperpigmentation. We anticipate launching IMCIVREE in the United States in 2026 for acquired hypothalamic obesity, a rare disease caused by hypothalamic injury that may impair MC4R pathway signaling. There are approximately 10,000 patients in the United States living with acquired hypothalamic obesity, with an annual incidence of 500 new cases. Similar prevalence and incidence are observed in Europe, and there are between 5,000 and 8,000 patients in Japan.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 40 items for RYTM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for RYTM spans 10-Q, 8-K.

Recent high-impact activity:

  • Two-Year Data: Setmelanotide Holds 18.8% BMI Cut in Hypothalamic Obesity
  • Second Bidder Emerges for Rhythm, Lifting Shares 4.2%
  • Shares Jump 28% on Reported $124/Share AstraZeneca Bid; NICE Expands IMCIVREE Access
  • AstraZeneca Reportedly Made ~$10B Takeover Approach for Rhythm Pharmaceuticals
  • Q3 Revenue Up 4% but RYTHM Withholds Q4 Outlook as Federal THC Ban Looms

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$189.76M
Net Income
-$196.54M
Diluted EPS
-$3.11
Op. Cash Flow
-$115.67M
Free Cash Flow
-$116.63M
Gross Profit
$170.26M
Operating Income
-$192.02M
Cash & Equivalents
$54.3M
Total Debt
$108.18M
Debt / Equity
0.78×
Net Margin
-103.6%
Shares Outstanding
67.21M sh
Source: 10-K · filed 2026-02-26 · accession 0001628280-26-012399

Short Interest & Short Volume

23.33 days to cover

FINRA reported short interest of 11,675,496 shares in RYTM as of the October 30, 2026 settlement, a 6.1% increase from the prior period — about 23.3 days to cover at its recent average daily volume. On November 20, 2026, 35.5% of RYTM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)11,675,496 shares as of October 30, 2026
Change vs prior period▲ 6.1%
Days to cover23.33 at avg daily volume of 500,502
Daily short volume (FINRA facilities)35.5% of 563,641 shares on November 20, 2026
5-day average short volume46.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with R →
$113.5 +1.01% today
52-week range · as of 2026-11-03 $74.5 – $122.2
Market cap
$7.79B
Volume
1.5M (1.0× avg)
3-mo avg 1.6M
Live data · 2026-11-21 14:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RYTM - Latest Insights

RYTM
Nov 16, 2026, 4:00 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $107.31
Real-time Price: $113.50 info
Change: +$6.19 (+6%) info
Market Cap: $7.79B info
RYTM
Nov 06, 2026, 11:06 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $109.39
Real-time Price: $113.50 info
Change: +$4.11 (+4%) info
Market Cap: $7.79B info
RYTM
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $109.75
Real-time Price: $113.50 info
Change: +$3.75 (+3%) info
Market Cap: $7.79B info
RYTM
Nov 04, 2026, 3:57 PM EST
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $95.21
Real-time Price: $113.50 info
Change: +$18.29 (+19%) info
Market Cap: $7.79B info
RYTM
Nov 04, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $85.70
Real-time Price: $113.50 info
Change: +$27.80 (+32%) info
Market Cap: $7.79B info
RYTM
Nov 04, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $88.42
Real-time Price: $113.50 info
Change: +$25.08 (+28%) info
Market Cap: $7.79B info
RYTM
Nov 03, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $86.44
Real-time Price: $113.50 info
Change: +$27.06 (+31%) info
Market Cap: $7.79B info
RYTM
Nov 03, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $89.50
Real-time Price: $113.50 info
Change: +$24.00 (+27%) info
Market Cap: $7.79B info
RYTM
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $93.44
Real-time Price: $113.50 info
Change: +$20.06 (+21%) info
Market Cap: $7.79B info
RYTM
Nov 03, 2026, 1:31 AM EST
Source: dpa-AFX
Importance Score:
8
Price at Filing: $93.44
Real-time Price: $113.50 info
Change: +$20.06 (+21%) info
Market Cap: $7.79B info
RYTM
Nov 02, 2026, 8:53 PM EST
Source: Reuters
Importance Score:
9
Price at Filing: $93.44
Real-time Price: $113.50 info
Change: +$20.06 (+21%) info
Market Cap: $7.79B info
RYTM
Oct 13, 2026, 7:30 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $87.53
Real-time Price: $113.50 info
Change: +$25.97 (+30%) info
Market Cap: $7.79B info
RYTM
Sep 22, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $98.82
Real-time Price: $113.50 info
Change: +$14.68 (+15%) info
Market Cap: $7.79B info
RYTM
Aug 24, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $110.00
Real-time Price: $113.50 info
Change: +$3.50 (+3%) info
Market Cap: $7.79B info
RYTM
Aug 11, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $111.49
Real-time Price: $113.50 info
Change: +$2.01 (+2%) info
Market Cap: $7.79B info
RYTM
Aug 04, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $105.78
Real-time Price: $113.50 info
Change: +$7.72 (+7%) info
Market Cap: $7.79B info
RYTM
Aug 04, 2026, 8:28 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $102.96
Real-time Price: $113.50 info
Change: +$10.54 (+10%) info
Market Cap: $7.79B info
RYTM
Aug 04, 2026, 7:49 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $105.00
Real-time Price: $113.50 info
Change: +$8.50 (+8%) info
Market Cap: $7.79B info
RYTM
Aug 04, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $105.00
Real-time Price: $113.50 info
Change: +$8.50 (+8%) info
Market Cap: $7.79B info
RYTM
Jun 15, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $89.70
Real-time Price: $113.50 info
Change: +$23.80 (+27%) info
Market Cap: $7.79B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets